KalVista Pharmaceuticals, Inc. · 1 day ago
Associate Director, Regulatory Affairs
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases. The Associate Director, Regulatory Affairs will contribute to the development of regulatory submissions and ensure ongoing regulatory compliance while collaborating cross-functionally to support strategic and operational requirements.
BiotechnologyDiabetesHealth Care
Responsibilities
Support IND/NDA/MAA preparation, submissions, assessment and post approval activities in designated territories, in close collaboration with the Global Regulatory Lead
Represent regulatory affairs in allocated launch teams as required
Provide regulatory support to business development, commercial, market access, pharmacovigilance, supply chain and quality functions
Working closely with other regulatory team members, to draft/put in place appropriate processes (SOPs) to ensure ongoing maintenance/regulatory compliance of marketing authorizations in designated markets
Contribute to KalVista’s Regulatory Intelligence process
Maintain compliance with KalVista’s Quality Management System and work to industry standards of GxP
Qualification
Required
Minimum of Degree in Chemistry, Pharmacy or a Biological Science
Minimum of 10 years' experience in Regulatory Affairs
Experience of FDA, Health Canada and LATAM regulatory submissions
Experience of post approval maintenance activities
Experience in developing and writing SOPs/Work Instructions for post commercial regulatory compliance processes
Outstanding communication (written and verbal) skills and willingness to share information
Ability to plan and execute projects to tight deadlines
An excellent team player with a proven ability to manage projects as part of an interdisciplinary team
Company
KalVista Pharmaceuticals, Inc.
For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE).
Funding
Current Stage
Public CompanyTotal Funding
$821.8MKey Investors
DRI Healthcare TrustRA Capital Management
2025-09-24Post Ipo Debt· $125M
2024-11-04Post Ipo Equity· $60M
2024-11-04Post Ipo Debt· $179M
Recent News
2025-12-22
Investor's Business Daily
2025-12-03
Company data provided by crunchbase